within Pharmacolibrary.Drugs.ATC.R;

model R03DC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.063,
    Cl             = 5.1 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 225 / 1000000,
    adminCount     = 1,
    Vd             = 0.0092,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Pranlukast is a leukotriene receptor antagonist used for the maintenance treatment of asthma and to relieve symptoms of allergic rhinitis. It works by blocking leukotriene D4 at the cysteinyl leukotriene receptor, reducing inflammation and bronchoconstriction. Pranlukast is approved for use in Japan and some other countries, but not in the United States or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Baek, IH, et al., &amp; Kim, MS (2014). Dissolution and oral absorption of pranlukast nanosuspensions stabilized by hydroxypropylmethyl cellulose. <i>International journal of biological macromolecules</i> 67 53–57. DOI:<a href=&quot;https://doi.org/10.1016/j.ijbiomac.2014.03.006&quot;>10.1016/j.ijbiomac.2014.03.006</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/24631786/&quot;>https://pubmed.ncbi.nlm.nih.gov/24631786</a></p></li><li><p>Asano, K, et al., &amp; Ishizaka, A (2009). Impact of pharmacokinetics and pharmacogenetics on the efficacy of pranlukast in Japanese asthmatics. <i>Respirology (Carlton, Vic.)</i> 14(6) 822–827. DOI:<a href=&quot;https://doi.org/10.1111/j.1440-1843.2009.01552.x&quot;>10.1111/j.1440-1843.2009.01552.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19703064/&quot;>https://pubmed.ncbi.nlm.nih.gov/19703064</a></p></li><li><p>Ha, ES, et al., &amp; Kim, MS (2015). Improving dissolution and oral bioavailability of pranlukast hemihydrate by particle surface modification with surfactants and homogenization. <i>Drug design, development and therapy</i> 9 3257–3266. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S87738&quot;>10.2147/DDDT.S87738</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26150699/&quot;>https://pubmed.ncbi.nlm.nih.gov/26150699</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R03DC02;
